CD8A and myelodysplastic syndrome: Here we present a detailed characterization of the CD8+ T cell immunogenicity, its long-term persistence, and its correlation with antibody response in patients with CCL and MDS who received up to three doses of the BNT162b2 mRNA vaccine.